Anika Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Anika Therapeutics

06/05/2023 03:05

* Anika Therapeutics Inc  ANIK.OQ   ANIK.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 9. 
    * The Bedford Massachusetts-based  company is expected to
report 
a 1.6% increase in revenue to $37.281 million from $36.69
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Anika Therapeutics
Inc is
for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Anika
Therapeutics Inc is $33​, above​ its last closing price
of $25.87. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.25       -0.24      -0.34     Missed  -41.7
 Sep. 30 2022  -0.25       -0.25      -0.15     Beat    40
 Jun. 30 2022  -0.21       -0.23      -0.20     Beat    11.8​
 Mar. 31 2022  -0.37       -0.36      -0.20     Beat    45.2
 ​​Dec.        -0.29       -0.25      -0.40     Missed  -58.4
 31 2021                                                
 Sep. 30 2021  -0.21       -0.21      0.04      Beat    119​
 Jun. 30 2021  -0.15       -0.15      0.45      Beat    406.8
 Mar. 31 2021  -0.13       -0.12      0.20      Beat    260
 This summary was machine generated May 6 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated